How likely are COVID-19 interventions to benefit the sickest patients?

Intensive Care Med. 2020 Jul;46(7):1441-1444. doi: 10.1007/s00134-020-06131-1. Epub 2020 Jun 9.

Authors

Anders Perner¹, Bharath Kumar Tirupakuzhi Vijayaraghavan², Balasubramanian Venkatesh³

Affiliations

¹ Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. anders.perner@rh.regionh.dk.
² Department of Critical Care, Apollo Hospitals, Chennai, India.
³ The George Institute for Global Health, Sydney, Australia.

No abstract available

Publication types

Editorial

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Antiviral Agents / therapeutic use*
Betacoronavirus*
COVID-19
COVID-19 Serotherapy
Coronavirus Infections / drug therapy*
Coronavirus Infections / epidemiology
Coronavirus Infections / therapy
Critical Illness / therapy
Humans
Immunization, Passive
Immunotherapy
Interferons / therapeutic use
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / epidemiology
Pneumonia, Viral / therapy
SARS-CoV-2

Substances

Adrenal Cortex Hormones
Antiviral Agents
Interferons